DOCS
The vibe: less champagne, still not panic
BofA just took a little air out of Doximity’s valuation balloon, cutting its price target to $47 from $56. But don’t confuse that with a full-on bearish breakup: the firm kept its Buy rating in place, so the message is more “temper your expectations” than “run for the exits.”
Why investors should care
Doximity has already been getting punished — the stock was quoted around $22.25 and has fallen 67% over the past six months, according to the article. So this isn’t exactly a fresh punch to the gut; it’s more like another reminder that analysts are still trying to model a business in transition.
The wrinkle here is that BofA framed the call around a transition-year outlook. Translation: the market probably wants clean, steady growth, but the company may be in one of those annoying stretches where the story is still being rewritten.
The analyst treadmill keeps spinning
The article also notes that Doximity has had a flurry of analyst action lately:
- Evercore ISI downgraded it to In Line from Outperform and cut its target to $25
- Freedom Capital Markets started coverage with a Buy and a $31 target
So if you’re trying to divine the future from Wall Street notes, good luck — the consensus seems to be somewhere between “modestly optimistic” and “please prove it.”
Big picture: Doximity still has believers, but the easy-money phase looks over. Now it has to earn the premium the old-fashioned way: by showing the market that the transition year isn’t a detour.